Merrimack Pharmaceuticals (NASDAQ:MACK)
The company's initial public offering of stock on the NASDAQ occurred on March 28, 2012. The company offered 14.3M shares each for $7. This was at the low end of the initial price range of $8-$10. The company had originally announced that they would offer 16.67M shares. The deal raised a total of approximately $100M. The lead manger of the deal was JP Morgan.